Strategic Focus: Manufacturing Operations Management (MOM) Software Trends In Pharma

Executive Summary

Pharmaceutical and biopharmaceutical manufacturers are accelerating digital transformation, as rising modality complexity, shifting global production patterns, regulatory pressures and growing reliance on AI reshape the demands placed on their operating environments. Firms are moving beyond traditional manufacturing execution system (MES) deployments to invest in integrated manufacturing operations management (MOM) platforms that connect design, production and quality, to strengthen resilience, improve efficiency and support faster, more compliant scale-up of new therapies. Market conditions are driving the adoption of modular, cloud ready systems that can be deployed at pace, while strategic vendor acquisitions are expanding portfolios to unify data from R&D through to commercial manufacturing. Real time quality technologies, such as process analytical technology (PAT), combined with digital twins and AI augmented decision support, are enabling the continuous verification of process health and reducing batch variability. As manufacturers work to regionalize production, modernize legacy architectures and prepare for more distributed operations, MOM software is emerging as the core orchestration layer that provides the visibility, governance and intelligence required for reliable, high quality and economically sustainable life sciences manufacturing.